| Summary: | This interim process statement has been produced to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs. These procedures are designed to ensure that a robust, quality-assured, commentary is developed for the NHS in an open, transparent and timely way, with appropriate input from key groups. ESUOMs support the use of unlicensed and off-label medicines for individual patients, where there are good clinical reasons for the use of an off-label or unlicensed medicine, usually when there is no licensed medicine for the condition requiring treatment, or it is not appropriate for that individual. They should not be considered to promote the use of unlicensed medicines solely for economic reasons. This interim process statement of ESUOMs will be superseded when the final process guide is issued later in 2012, following engagement and discussions with key groups
|
|---|